Com-pare2 Flu Relief
Anas Barbariae
Trp Company
Human Otc Drug
NDC 17312-179Com-pare2 Flu Relief also known as Anas Barbariae is a human otc drug labeled by 'Trp Company'. National Drug Code (NDC) number for Com-pare2 Flu Relief is 17312-179. This drug is available in dosage form of Tablet. The names of the active, medicinal ingredients in Com-pare2 Flu Relief drug includes Cairina Moschata Heart/liver Autolysate - 200 [hp_C]/1 . The currest status of Com-pare2 Flu Relief drug is Active.
Drug Information:
| Drug NDC: | 17312-179 |
| The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. |
| Proprietary Name: | Com-pare2 Flu Relief |
| Also known as the trade name. It is the name of the product chosen by the labeler. |
| Product Type: | Human Otc Drug |
| Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. |
| Non Proprietary Name: | Anas Barbariae |
| Also known as the generic name, this is usually the active ingredient(s) of the product. |
| Labeler Name: | Trp Company |
| Name of Company corresponding to the labeler code segment of the ProductNDC. |
| Dosage Form: | Tablet |
| The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. |
| Status: | Active |
| FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved. |
| Substance Name: | CAIRINA MOSCHATA HEART/LIVER AUTOLYSATE - 200 [hp_C]/1
|
| This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. |
| Route Details: | ORAL
|
| The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
Marketing Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Marketing Category: | UNAPPROVED HOMEOPATHIC |
| Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
| Marketing Start Date: | 15 Feb, 2021 |
| This is the date that the labeler indicates was the start of its marketing of the drug product. |
| Marketing End Date: | 25 Dec, 2025 |
| This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached. |
| Listing Expiration Date: | 31 Dec, 2024 |
| This is the date when the listing record will expire if not updated or certified by the firm. |
OpenFDA Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Manufacturer Name: | TRP Company
|
| Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC. |
| Original Packager: | Yes
|
| Whether or not the drug has been repackaged for distribution. |
| UPC: | 0858961001792
|
| UPC stands for Universal Product Code. |
| UNII: | RN2HC612GY
|
| Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information. |
Packaging Information:
| Package NDC | Description | Marketing Start Date | Marketing End Date | Sample Available |
|---|
| 17312-179-30 | 2 BLISTER PACK in 1 BOX (17312-179-30) / 15 TABLET in 1 BLISTER PACK | 15 Feb, 2021 | N/A | No |
| Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. |
Purpose:
Purpose anas barbariae ......shorten the length and severity of flu related symptoms
Product Elements:
Com-pare2 flu relief anas barbariae silicon dioxide lactose, unspecified form mannitol cairina moschata heart/liver autolysate cairina moschata heart/liver autolysate crospovidone magnesium stearate microcrystalline cellulose sorbitol copovidone k25-31
Indications and Usage:
Uses* according to homeopathic indications, these ingredients provide temporary relief of flu related symptoms such as: ⢠fever, chills, overall achiness, headache, general weakness, and tiredness; after serious causes have been ruled out by a physician. * these statements are based upon traditional homeopathic practice. they have not been reviewed by the food and drug administration.
Warnings:
Warnings a physician should always be consulted to rule out serious causes . ⢠this product is intended to complement, not replace, standard medical treatment. ⢠initial worsening of symptoms may occur. ⢠if pregnant or breast-feeding, ask a health professional before use. ⢠keep out of reach of children. ⢠in case of overdose, get medical help or contact a poison control center right away.
Do Not Use:
Warnings a physician should always be consulted to rule out serious causes . ⢠this product is intended to complement, not replace, standard medical treatment. ⢠initial worsening of symptoms may occur. ⢠if pregnant or breast-feeding, ask a health professional before use. ⢠keep out of reach of children. ⢠in case of overdose, get medical help or contact a poison control center right away.
Dosage and Administration:
Directions directions ⢠suitable for adults and children ages 2 and over. children under the age of 2: consult a physician before use. dissolve entire tablet under tongue. ⢠do not chew or swallow whole. ⢠take 1 tablet every six hours. ⢠take at least 10 minutes before or at least 10 minutes after eating or drinking. ⢠homeopathic remedies may not be effective for everyone. individual results may vary.
Stop Use:
Stop use and ask a doctor if: stop use and ask a doctor if: ⢠you experience worsening symptoms. ⢠any new symptoms appear. ⢠symptoms last longer than 3 days.
Package Label Principal Display Panel:
Label label